Wordt geladen...
A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” mutant of Bcr-Abl
The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I ‘gatekeeper’ mutation. Here we describe a Type-II T315I inhibitor GNF-7, based upon a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffold whic...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4134510/ https://ncbi.nlm.nih.gov/pubmed/20604564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm901808w |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|